Belimumab
A decade under Benlysta: Review touts how historic lupus drug continues to impact therapy
In the 10 years since its first FDA approval for systemic lupus erythematosus in 2011, belimumab has altered the “SLE treatment paradigm,” amassing a body of evidence establishing it as a disease-modifying therapy, according to a review article.
FDA approves Saphnelo, first new lupus treatment since 2011
The FDA has approved AstraZeneca’s anifrolumab-fnia, a first-in-class type I interferon receptor antagonist, for treatment of adults with moderate to severe systemic lupus erythematosus, according to a press release.
FDA approves Benlysta, first treatment for lupus nephritis
The FDA has approved belimumab in intravenous and subcutaneous formulations for the treatment of lupus nephritis in adult patients who are receiving standard therapy, according to a press release from GlaxoSmithKline.
Belimumab plus standard therapy boosts renal outcomes, reduces steroids in lupus nephritis
Adding belimumab to standard therapy improves renal outcomes, biomarker levels and overall disease activity among patients with lupus nephritis, according to a speaker at ACR Convergence 2020.